Renal cell carcinoma is a serious form of kidney cancer that can be challenging to treat successfully. Sunitinib is a drug used to treat advanced renal cell cancer, but often the cancer returns. Doctors are therefore seeking more effective therapies.
In this study, researchers are comparing the safety and effectiveness of sunitinib treatment with another drug called cabozantinib (XL184). Sunitinib inhibits the development of blood vessels that tumors need to grow and spread. Cabozantinib is a drug that blocks several proteins (called MET, RET, and vascular endothelial growth factor receptor 2) that help keep cancer cells alive. It is approved for treating thyroid cancer, but its use for renal cell carcinoma is considered investigational.
Patients in this study will be randomly assigned to receive either cabozantinib or sunitinib. Both drugs are taken orally (by mouth).